GCCL and GemPharmatech Sign MOU to Advance Global Drug Discovery and Development Services
GCCL, a South Korea-based leading provider of clinical trial sample analysis, and GemPharmatech, a global provider of in vivo efficacy testing and genetically engineered animal models, announced the signing of a Memorandum of Understanding (MOU) to promote mutual collaboration in delivering integrated drug discovery and development services to pharmaceutical and biotechnology companies worldwide.
The signing event, which took place on July 21 in Seoul, was attended by Kwan Goo Cho, CEO of GCCL; Dr. Xiang Gao, Founder and Chairman of GemPharmatech, LTD; and Dr. Brandy Wilkinson, North America CEO of GemPharmatech, LLC.
Under the terms of the MOU, GCCL and GemPharmatech will explore joint initiatives that combine GCCL's integrated clinical-stage central lab capabilities, including bioanalysis and sample management, with GemPharmatech's preclinical in vivo efficacy testing, disease models, and genetically engineered mouse model portfolio.
The partnership is intended to give pharmaceutical and biotech sponsors a more streamlined path from preclinical proof-of-concept through clinical trial execution, reducing the friction of working across separate vendors as programs advance from bench to bedside. The collaboration is expected to support a broad range of disease areas and emerging therapeutic modalities, including areas such as in vivo CAR-T, by aligning preclinical research services with clinical-stage analytical support.
